期刊文献+

15肽介导的聚吡咯修饰的纳米金花对小鼠脏器的损伤及其体内代谢分析

Injury of gold nanoflower modified with 15 peptide-mediated polyrrole on mouse organ and in vivo metabolism of the drug
原文传递
导出
摘要 目的分析15肽介导的聚吡咯修饰的纳米金花(gold nanoflower modified with 15 peptide mediated polyrrole,15P-PPy-NPS)对小鼠脏器的损伤及体内代谢情况。方法向SKOV-3肿瘤荷瘤裸鼠尾静脉注射15P-PPy-NPS,采用电感耦合等离子体质谱(inductively coupled plasma-mass spectrometry,ICP-MS)技术分析不同时间点Au元素在裸鼠血液和主要脏器中的沉积及代谢情况。将裸鼠主要脏器制成石蜡切片,利用TUNEL试剂盒及PI碘化丙啶作核染色双标染色,观察裸鼠主要脏器损伤情况。结果 15P-PPy-NPS通过血液进入裸鼠体内,可被肝脏代谢,少量蓄积未造成明显的组织损伤。结论 15P-PPy-NPS对裸鼠肝脏、肾脏、脾脏等主要脏器未造成明显损伤,可经肝脏代谢,用于生物治疗和光热治疗,具有较好的安全性和可靠性。 Objective To analyze the injury of gold nanoflower modified with 15 peptide mediated polyrrole(15P-PPyNPs) on mouse organ as well as in vivo metabolism of the drug. Methods SKOV-3 tumor-bearing nude mice were injected i. v. with 15P-PPy-NPS, of which the accumulation and metabolism of Au element in blood and major organs at various time points were analyzed by inductively coupled plasma-mass spectrometry(ICP-MS). The main organs of nude mice were prepared into paraffin sections and observed for the injury by immunofluorescence staining. Results The 15P-PPy-NPs may enter the body of nude mice through the blood, then be metabolized by the liver, and cause a small amount of accumulation with no significant tissue damage. Conclusion The 15P-PPy-NPS showed no injury on the main organs such as liver, kidney and spleen of nude mice, which might be metabolized through liver and used for biological and photothermal therapies, and showed high safety and reliability.
出处 《中国生物制品学杂志》 CAS CSCD 2016年第9期928-931,共4页 Chinese Journal of Biologicals
关键词 15肽介导的聚吡咯修饰的纳米金花 脏器 损伤 体内代谢 Gold nanoflower modified with 15 peptide mediated polyrrole(15P-PPy-NPS) Organ Injury In vivo metabolism
  • 相关文献

参考文献8

二级参考文献85

  • 1韩焕兴,范列英,胡栋平,孔宪涛.人源抗乙肝病毒表面抗原单克隆抗体的抗原结合活性[J].中华医学杂志,1996,76(6):467-468. 被引量:5
  • 2Wittem H,Jone K,Wltng J,et al.Structure function relationships in the lymphatic system and implications for cancer biology[J].Cancer Metastasis Rev,2006,25(2):159-184.
  • 3Dumont DJ,Jussila L,Taipale J,et al.Cardiovascular failure in mouse embryos deficient in VEGF receptor-3[J].Science,1998,282(5390):946-949.
  • 4Padera TP,Kadambi A,di-Tomaso E,et al.Lymphatic metastasis in the absence of functional intratumor lymphatic[J].Science,2002,296(5574):1883-1886.
  • 5Breiteneder-Geleff S,Soleiman A,Kowalski H,et al.Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries:podoplanin as a specific marker for lymphatic endothelium.Am J Pathol,1999,154(2):385-394.
  • 6Hong YK,Harvey N,Noh YH,et al.Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate[J].Bey Dyn,2002,225(3):351-357.
  • 7Joukov V,Pajusola K,Kaipainen A,et al.A novel vascular endothelial growth factor,VEGF-C,is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases[J].EMBO J,1996,15:290-298.
  • 8Achen MG,Jeltsch M,Kukk E,et al.Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyresine kinases VEGF receptor-2 (Flk-1) and VEGF receptor-3 (Flt-4)[J].PNAS,1998,95:548-553.
  • 9Su JL,Yen C J,Chen PS,Chuang SE,Hong CC,Kuo IH,et al.The role of the VEGF-C/VEGFR-3 axis in cancer progression[J].BrJ Cancer,2007,96:541-545.
  • 10Jeltsch M,Kaipainen A,Joukov V,et al.Hyperplasia of lymphatic vessels in VEGF-C transgenic mice[J].Science,1997,276(5317):1423-1425.

共引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部